Streetbeat News

Products Services

KZIA

Kazia Therapeutics Limited presented data at the American Association for Cancer Research (AACR) Annual Meeting, showcasing their latest research findings in cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:10 pm

BGNE

The Max Foundation, BeiGene, and the BeiGene Foundation have initiated the distribution of BRUKINSA, a treatment for Chronic Lymphocytic Leukemia, to patients in low- and middle-income countries, starting with Armenia and Nepal. This effort is part of a collaboration aimed at improving access to this critical medication in 29 countries.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:08 pm

IMNN

IMUNON, Inc. (NASDAQ:IMNN) has filed an IND application with the FDA for IMNN-101, a DNA-based vaccine for COVID-19, with Phase 1 human trials expected to start in Q2 2024. The vaccine utilizes IMUNON's proprietary PlaCCine platform and aims to demonstrate superior durability and immune response compared to mRNA vaccines. Preclinical data shows promising results, and the company aims to attract partners for further development.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 12:07 pm

TAK

Takeda announced positive interim results from a Phase 2 study of Mezagitamab (TAK-079) for treating Primary Immune Thrombocytopenia, showing it to be safe and well-tolerated. The company plans to initiate a global Phase 3 trial in Fiscal Year 2024, as its late-stage pipeline, including five new molecular entities, continues to advance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:07 pm

OCGN

Ocugen has completed dosing subjects in Cohort 1 of its Phase 1/2 clinical trial for OCU410, aimed at evaluating the safety and efficacy of the treatment for Geographic Atrophy.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:05 pm

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) announced the publication of preclinical research and the grant of a U.S. patent for its Infectimune® platform, demonstrating significant advancements in influenza vaccine development. The research showed Infectimune®'s ability to improve the quantity and quality of CD4 T cells, positioning it as a leading candidate for next-generation vaccines. The USPTO granted Patent Number 11,904,015 for vaccine compositions using Infectimune®, enhancing PDS Biotech's intellectual property portfolio.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 12:04 pm

NRBO

NeuroBo Pharmaceuticals has received approval from the Safety Review Committee to proceed with its Phase 2a clinical trial for DA-1241, a treatment for MASH.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:04 pm

CPRX

Catalyst Pharmaceuticals announced the U.S. commercial launch of AGAMREE for Duchenne Muscular Dystrophy (DMD) treatment in patients aged two and older. AGAMREE, approved by the FDA on October 26, 2023, is now available by prescription. It offers a novel alternative to current steroid treatments, potentially reducing side effects and improving quality of life for DMD patients. Catalyst's Pathways Program supports patient access and education. AGAMREE has shown comparable efficacy to standard corticosteroids with a better side effect profile in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:01 pm

GOOGL

Google has implemented restrictions on its AI chatbot, Gemini, to limit responses to election-related queries, aiming to prevent misinformation. This move is part of Google's election integrity strategy, especially relevant as India approaches its elections. The restrictions are already in effect in India, where Gemini directs users to Google Search for questions about elections in the U.S., U.K., and South Africa, but still answers queries on Indian politics. This decision aligns with global concerns over AI's role in spreading election misinformation and follows regulatory actions in India requiring tech companies to seek approval before deploying certain AI tools.

Portfolio Pulse from Benzinga Neuro

March 13, 2024 | 12:01 pm

AAPL

GOOG

SPOT

Spotify Technology SA (NYSE:SPOT) is rolling out a beta version of music videos for premium users in 11 markets, featuring artists like Ed Sheeran and Doja Cat. This move, aimed at enhancing user engagement, follows similar offerings by Alphabet Inc.'s (NASDAQ:GOOG) YouTube Music. Spotify's initiative comes amid a subscription fee increase in France due to a new tax and a recent antitrust win against Apple Inc. (NASDAQ:AAPL). Spotify's shares saw a slight decrease of 0.18% to close at $257.62.

Portfolio Pulse from Rounak Jain

March 13, 2024 | 11:52 am